このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Enovis マネジメント

マネジメント基準チェック /34

Enovis'の CEO はMatt Trerotolaで、 Jul2015年に任命され、の在任期間は 9.08年です。の年間総報酬は$ 10.77Mで、 10%給与と90%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.33%を直接所有しており、その価値は€ 7.92M 。経営陣と取締役会の平均在任期間はそれぞれ5.6年と4年です。

主要情報

Matt Trerotola

最高経営責任者

US$10.8m

報酬総額

CEO給与比率	10.0%
CEO在任期間	9.2yrs
CEOの所有権	0.3%
経営陣の平均在職期間	5.6yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Enovis の収益と比較して、Matt Trerotola の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 28 2024	n/a	n/a	-US$107m
Mar 29 2024	n/a	n/a	-US$103m
Dec 31 2023	US$11m	US$1m	-US$54m
Sep 29 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$159m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$12m	US$1m	-US$39m
Sep 30 2022	n/a	n/a	US$1m
Jul 01 2022	n/a	n/a	US$54m
Apr 01 2022	n/a	n/a	-US$109m
Dec 31 2021	US$14m	US$1m	-US$103m
Oct 01 2021	n/a	n/a	-US$48m
Jul 02 2021	n/a	n/a	-US$18m
Apr 02 2021	n/a	n/a	US$21m
Dec 31 2020	US$8m	US$1m	-US$75m
Oct 02 2020	n/a	n/a	US$53m
Jul 03 2020	n/a	n/a	US$39m
Apr 03 2020	n/a	n/a	US$42m
Dec 31 2019	US$8m	US$1m	US$8m
Sep 27 2019	n/a	n/a	US$10m
Jun 28 2019	n/a	n/a	US$21m
Mar 29 2019	n/a	n/a	US$66m
Dec 31 2018	US$3m	US$1m	US$108m
Sep 28 2018	n/a	n/a	-US$115m
Jun 29 2018	n/a	n/a	-US$84m
Mar 30 2018	n/a	n/a	-US$92m
Dec 31 2017	US$3m	US$1m	US$28m

報酬と市場: Mattの総報酬 ($USD 10.77M ) は、 German市場 ($USD 2.27M ) の同規模の企業の平均を上回っています。

報酬と収益: Mattの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Matt Trerotola (57 yo)

9.2yrs

在職期間

US$10,774,635

報酬

Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Matthew Trerotola	CEO & Chairman	9.2yrs	US$10.77m	0.32% $ 6.8m
Phillip Berry	Senior VP & CFO	1.7yrs	US$2.36m	0.063% $ 1.3m
Patricia Lang	Senior VP & Chief Human Resources Officer	5.7yrs	US$2.07m	0.040% $ 854.0k
Daniel Pryor	Executive Vice President of Strategy & Business Development	11.2yrs	US$4.75m	0.15% $ 3.3m
Brady Shirley	Executive Advisor & Director	7.8yrs	US$5.20m	0.11% $ 2.3m
John Kleckner	VP, Controller & Chief Accounting Officer	2.3yrs	データなし	0.012% $ 246.0k
Derek Leckow	Vice President of Investor Relations	no data	データなし	データなし
Bradley Tandy	Senior VP & Chief Legal Officer	5.6yrs	データなし	0.046% $ 964.9k
Katie Sweet	Vice President of Corporate Communication	no data	データなし	データなし
Tim Czartoski	President of U.S. Surgical and Global Product & Enabling Technologies	no data	データなし	データなし
Terry Ross	Group President Prevention & Recovery	no data	データなし	0.035% $ 746.4k
Brian Hanigan	Secretary	no data	データなし	データなし

5.6yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: C520の経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Matthew Trerotola	CEO & Chairman	9.2yrs	US$10.77m	0.32% $ 6.8m
Brady Shirley	Executive Advisor & Director	2.4yrs	US$5.20m	0.11% $ 2.3m
Sharon Wienbar	Lead Independent Director	8.3yrs	US$316.46k	0% $ 0
A. Perfall	Independent Director	14yrs	US$308.93k	0.0044% $ 94.1k
Angela Lalor	Independent Director	2.4yrs	US$296.46k	0% $ 0
Rajiv Vinnakota	Independent Director	16.3yrs	US$298.93k	0.039% $ 822.0k
Liam Kelly	Independent Director	4.7yrs	US$283.93k	0.023% $ 493.6k
Philip Okala	Independent Director	3.6yrs	US$283.93k	0.015% $ 313.2k
Barbara Bodem	Independent Director	2.4yrs	US$283.93k	0.015% $ 313.2k
Christine Ortiz	Independent Director	2.4yrs	US$283.93k	0.015% $ 313.2k

4.1yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: C520の取締役会は経験豊富であると考えられます ( 3.9年の平均在任期間)。

Enovis マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Corporation, Annual General Meeting, May 20, 2024

Enovis Corporation Announces Leadership Transition Plan

High number of new directors

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

High number of new directors

Recent updates

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

New minor risk - Shareholder dilution

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$1.32 loss per share (vs US$0.42 loss in 1Q 2023)

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.99 loss per share (vs US$0.72 loss in FY 2022)

Enovis Corporation Provides Earnings Guidance for the Year 2024

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

No longer forecast to breakeven

Enovis Corporation Announces Leadership Transition Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$1.22 loss in 3Q 2022)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Now 21% undervalued

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$2.23 profit in 2Q 2022)

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.71 loss in 1Q 2022)

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.84 profit in FY 2021)

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings released: US$1.22 loss per share (vs US$0.51 profit in 3Q 2021)

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$2.23 (vs US$0.59 in 2Q 2021)

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis Corporation to Report Q2, 2022 Results on Aug 04, 2022

Enovis Corporation (NYSE:ENOV) acquired Insight Medical Systems, Inc.

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

Enovis Corporation Launches Arsenal Ankle Plating System

High number of new directors

Enovis Corporation Reaffirms Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.57 in 1Q 2021)

High number of new directors

Enovis Corporation to Report Q1, 2022 Results on May 10, 2022

Enovis Corporation Announces Board Changes

Investor sentiment deteriorated over the past week

Enovis Corporation completed the Spin-Off of ESAB Corporation (NYSE:ESAB).

Colfax Corporation Announces Board Resignations, Effective Upon the Consummation of the Separation of its Fabrication Technology Business

Executive VP of Finance & CFO recently sold €64k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Colfax Corporation Provides Earnings Guidance for the Year 2022

Colfax Corporation Announces Management Changes, Effective May 13, 2022

Third quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 in 3Q 2020)

Independent Director recently sold €88k worth of stock

Co-Founder & Chairman of the Board recently bought €9.8m worth of stock

Second quarter 2021 earnings released: EPS US$0.20 (vs US$0.026 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.057 in 1Q 2020)

Colfax Corporation has completed a Follow-on Equity Offering in the amount of $644 million.

Colfax Corporation Announces Executive Changes for Two Differentiated, Independent, and Publicly-Traded Companies

Colfax Corporation Appoints Philip Okala to its Board of Directors

New 90-day high: €35.20

Full year 2020 earnings released: EPS US$0.44 (vs US$0.062 in FY 2019)

Revenue beats expectations

マネジメント基準チェック /34